These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 29871535)

  • 1. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
    van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
    Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs.
    Muñoz-Barrera L; Perez-Sanchez C; Ortega-Castro R; Corrales S; Luque-Tevar M; Cerdó T; Sanchez-Pareja I; Font P; Lopez-Mejías R; Calvo J; Abalos-Aguilera MC; Ruiz-Vilchez D; Segui P; Merlo C; Perez-Venegas J; Ruiz Montesino MD; Rodriguez-Escalera C; Barco CR; Fernandez-Nebro A; Vazque NM; Marenco JL; Montañes JU; Godoy-Navarrete J; Cabezas-Lucena AM; Estevez EC; Aguirre MA; González-Gay MA; Barbarroja N; Escudero-Contreras A; Lopez-Pedrera C
    Biomed Pharmacother; 2024 Apr; 173():116357. PubMed ID: 38479179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of cardiovascular disease risk in patients with rheumatoid arthritis.
    Ahmed O; Krishnamurthy V; Kaba RA; Tahir H
    Expert Opin Pharmacother; 2022 Jun; 23(8):947-958. PubMed ID: 35575484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.
    Barbhaiya M; Solomon DH
    Curr Opin Rheumatol; 2013 May; 25(3):317-24. PubMed ID: 23466960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cardiovascular disease in rheumatoid arthritis.
    Hollan I; Dessein PH; Ronda N; Wasko MC; Svenungsson E; Agewall S; Cohen-Tervaert JW; Maki-Petaja K; Grundtvig M; Karpouzas GA; Meroni PL
    Autoimmun Rev; 2015 Oct; 14(10):952-69. PubMed ID: 26117596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).
    Mourouzis IS; Manolis AS; Pantos C
    Curr Vasc Pharmacol; 2020; 18(5):455-462. PubMed ID: 31566134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.
    Choy E; Ganeshalingam K; Semb AG; Szekanecz Z; Nurmohamed M
    Rheumatology (Oxford); 2014 Dec; 53(12):2143-54. PubMed ID: 24907149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
    Giles JT
    Curr Rheumatol Rep; 2016 May; 18(5):27. PubMed ID: 27032790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China.
    Li C; Wang XR; Ji HJ; Zhang XY; Li XF; Wang LZ; Wang CH; Wang YF; Yang R; Wang GC; Lu X; Zhu P; Chen LN; Jin HT; Liu JT; Liu XY; Sun L; Chen HY; Wei P; Wang JX; Cui LF; Shu R; Liu BL; Zhang ZL; Li GT; Li ZB; Yang J; Li JF; Jia B; Zhang FX; Tao JM; Han SL; Lin JY; Wei MQ; Liu XM; Ke D; Hu SX; Ye C; Yang XY; Li H; Huang CB; Gao M; Lai B; Li XF; Song LJ; Wang Y; Wang XY; Tang YD; Su Y; Mu R; Li ZG
    Clin Rheumatol; 2017 May; 36(5):1023-1029. PubMed ID: 28342151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis.
    Cho SK; Kim D; Won S; Lee J; Park B; Jang EJ; Bae SC; Sung YK
    Semin Arthritis Rheum; 2018 Feb; 47(4):501-506. PubMed ID: 28863826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
    Day AL; Singh JA
    Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
    Drakopoulou M; Soulaidopoulos S; Oikonomou G; Tousoulis D; Toutouzas K
    Curr Vasc Pharmacol; 2020; 18(5):488-506. PubMed ID: 32056527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.
    Chighizola C; Schioppo T; Ingegnoli F; Meroni PL
    Curr Vasc Pharmacol; 2012 Sep; 10(5):639-46. PubMed ID: 22272912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
    Fragoulis GE; Panayotidis I; Nikiphorou E
    Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.
    Innala L; Möller B; Ljung L; Magnusson S; Smedby T; Södergren A; Öhman ML; Rantapää-Dahlqvist S; Wållberg-Jonsson S
    Arthritis Res Ther; 2011 Aug; 13(4):R131. PubMed ID: 21843325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
    Myasoedova E
    Curr Opin Rheumatol; 2017 May; 29(3):277-284. PubMed ID: 28207495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.
    Lim DT; Cannella AC; Michaud KD; Mikuls TR
    Curr Rheumatol Rep; 2014 Nov; 16(11):459. PubMed ID: 25315196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.